Lee Flowers Acquires 962 Shares of HCW Biologics Inc. (NASDAQ:HCWB) Stock

HCW Biologics Inc. (NASDAQ:HCWB) SVP Lee Flowers bought 962 shares of the company’s stock in a transaction dated Thursday, May 8th. The stock was bought at an average price of $26.00 per share, for a total transaction of $25,012.00. Following the acquisition, the senior vice president now directly owns 5,720 shares of the company’s stock, valued at approximately $148,720. This represents a 20.22 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

HCW Biologics Trading Down 20.0 %

Shares of NASDAQ:HCWB opened at $5.72 on Friday. HCW Biologics Inc. has a 1-year low of $5.22 and a 1-year high of $100.80. The stock has a market cap of $6.42 million, a PE ratio of -5.72 and a beta of 0.85. The stock’s fifty day simple moving average is $10.01 and its two-hundred day simple moving average is $14.78.

HCW Biologics (NASDAQ:HCWB) last released its quarterly earnings results on Friday, March 28th. The company reported ($3.20) earnings per share for the quarter. HCW Biologics had a negative return on equity of 2,516.84% and a negative net margin of 1,067.82%. The firm had revenue of $0.40 million for the quarter.

About HCW Biologics

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.